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Suicide gene therapy combined with chemokines provides significant
antitumor efficacy. Coexpression of suicide gene and monocyte
chemoattractant protein-1 (MCP-1) increases antitumor effects in
murine models of hepatocellular carcinoma (HCC) and colon cancer.
However, it is unclear whether the doses administered achieved the
maximum antitumor effects. We evaluated antitumor effects of
various amounts of recombinant adenovirus vector (rAd) expressing
MCP-1 in the presence of a suicide gene in a murine model of HCC.
HCC cells were transplanted subcutaneously into BALB/c nude mice,
and transduced with a fixed amount of Ad-tk harboring the suicide
gene, HSV-tk, and various doses of Ad-MCP1 harboring MCP-1
(ratios of 1:1, 0.1:1, and 0.01:1 relative to Ad-tk). Growth of primary
tumors was suppressed when treated with Ad-tk plus Ad-MCP1 (1:1
and 1:0.1) as compared with Ad-tk alone. The antitumor effects
against tumor rechallenge tended to be high in the Ad-tk plus Ad-
MCP1 group (1:0.1). The effects were dependent on production of
Th1 type-cytokines. Delivery of an optimal amount of rAd expressing
MCP-1 enhanced the antitumor effects of suicide gene therapy
against HCC by M1 macrophage activation, suggesting that this is a
plausible form of cancer gene therapy to prevent HCC progression
and recurrence. (Cancer Sci 2008; 99: 2075–2082)
Cancer gene therapy using combinations of various genes,such as suicide and cytokine genes, to enhance tumor
regression therapy is widely used.(1,2) Previously, we reported
that the coexpression of herpes simplex virus thymidine kinase
(HSV-tk) and monocyte chemoattractant protein-1 (MCP-1)
showed enhanced antitumor effects in models of hepatocellular
carcinoma (HCC)(3) and colon cancer,(4) and these antitumor
effects were dependent on the activation of macrophages.(3) MCP-
1 is a chemokine that regulates the recruitment of monocytes/
macrophages to inflammatory sites and tumor tissues as well as
their activation, including lysosomal enzyme release and tumoricidal
activity,(5) and is functional in both mice and humans.(6)
However, MCP-1 was reported to be destructive in some tumor
models,(6,7) but protective in others.(8) Monocytes/macrophages
recruited by MCP-1 have dual functions in that they can prevent
the establishment and spread of tumor cells,(6) and simultaneously
support tumor growth and dissemination.(8) This ambivalent
relationship reflects the elevated functional plasticity of macrophages,
which are able to express different functional programs in
response to different microenvironment signals, as exemplified
in the M1 (classical)–M2 (alternative or non-classical) paradigm
of macrophage polarization.(9)
On the other hand, although double infection methods are used
to enhance antitumor effects in cancer gene therapy, significant
antitumor effects have been reported in some studies,(4,10) but not
in others.(11,12) Moreover, it is not clear how the antitumor effects
are affected by differences in the doses administered. In the
present study, various amounts of recombinant adenovirus vector
(rAd) expressing the MCP-1 gene were delivered into cells along
with the same amount of HSV-tk to determine the optimal dosage
of MCP-1 for induction of stronger antitumor effects in double
infection methods. Furthermore, we also examined the involve-
ment of macrophage immune responses in these effects. Here,
we demonstrated that treatment with the 1:0.1 ratio of Ad-HSV-tk
(Ad-tk) plus Ad-MCP1 tended to exert antitumor immunity,
suggesting that there may be an optimal amount of Ad-MCP1 in
suicide gene therapy. In addition, it is possible that the antitumor
responses seen in the HSV-tk plus MCP-1 system were associated
with increased Th1 (T helper 1)–type cytokine production by
activated M1 macrophage. These findings will be of value in
cancer gene therapy.
Materials and Methods
Recombinant adenoviruses. rAds harboring the human MCP-1
(Ad-MCP1), HSV-tk (Ad-tk), and lacZ (Ad-lacZ), and driven by
the CAG promoter were prepared, purified, and titrated according
to the protocols supplied by the manufacturer (Takara Bio, Shiga,
Japan), as described.(13) The rAds were purified on cesium
gradients and their titers were determined by the 50% tissue
culture infectious dose (TCID50).
Cell lines and culture. The human HCC cell line Huh7 and the
mouse HCC cell line BNL 1ME A.7R.1 (BNL) were cultured in
Dulbecco’s minimal essential medium (Gibco, Long Island, NY,
USA) supplemented with 10% heat-inactivated fetal bovine
serum (Gibco).
Enzyme-linked immunosorbent assay (ELISA) for MCP-1. Aliquots
of 1 × 105 Huh7 cells were seeded in 1.0 mL of culture media in
24-well tissue culture plates. Twenty-four h later, the cells were
infected with each rAd at a multiplicity of infection (MOI) of
10, and the medium was collected 48 h later. On the other hand,
in some experiments, ganciclovir (GCV; Tanabe Pharmaceutical
Drug, Tokyo, Japan) (10 μg/mL) was added 72 h later, and the
medium was collected and replaced with the same volume of
fresh medium every 24 h. The concentration of MCP-1 in the
medium collected from each well was determined by ELISA as
described.(14)
In vivo studies in nude mice. The following investigations were
performed in accordance with the guidelines of our Institutional
Animal Care and Use Committee. Six-week-old male athymic
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nude mice (BALB/cA Jcl-nu; CLEA Japan, Tokyo, Japan) were
injected subcutaneously with 1 × 107 HuH7 cells at the both
sides of the flank on day 0. On days 3 and 4, 1 × 107 TCID50(100 μL) of Ad-tk, Ad-lacZ, or Ad-tk (1 × 107 TCID50, fixed
dose) plus Ad-MCP1 (1, 0.1, 0.01, or 0.001 × 107 TCID50,
changed dose) were injected into the tumor. Then, 75 mg/kg of
GCV was administered into the peritoneal cavity daily for the
next 5 consecutive days (day 5–9), and tumor size was measured
every 3 days. Tumor volumes were calculated using the formula:
Gene expression analysis (real-time reverse transcription–polymerase
chain reaction [RT-PCR]). Total RNA was extracted from tumor
tissues or spleens resected after treatment of the tumor with each
rAd, using a Total Cellular RNA Isolation Kit (Ambion, St. Austin,
TX, USA), in accordance with the manufacturer’s protocol. The
RNA was reverse transcribed with a TaqMan reverse transcription
reagent kit (PE Applied Biosystems, Foster City, CA, USA) using
random hexamer primers. Gene expression was analyzed by
real-time RT-PCR using TaqMan Universal Master Mix on an
ABI PRISM 7900 Sequence Detection System (PE Applied
Biosystems). The PCR primer pairs for mouse interleukin (IL)–10,
IL-12, IL-18, IFN-γ, VEGF, and 18S rRNA were obtained from
the TaqMan assay reagent library. Data for whole samples were
normalized to 18S rRNA and then expressed as the fold change
in mRNA expression as compared with control samples treated
with phosphate-buffered saline (PBS).
Immunohistochemical analysis. Tumor tissues were resected on
day 10. The tissue samples were embedded in OCT compound
(Sakura Finetek, Torrance, CA, USA) and snap-frozen in liquid
nitrogen. Cryostat sections of frozen tissues were fixed in
cold acetone for 10 min, followed by three rinses in PBS. To
avoid non-specific staining, avidin and biotin in the tissues were
blocked using a blocking kit (Vector Laboratories, Burlingame,
CA, USA). The slides were subsequently incubated with antibodies
(Abs) against Mac-1 (M1/70; Pharmingen, San Diego, CA, USA)
for 30 min at room temperature. Negative controls included
staining with non-specific Ab of the corresponding isotype and
subsequent staining with secondary Ab. The reactions were
visualized using a VECTASTAIN ABC Standard Kit (Vector
Laboratories), followed by counterstaining with hematoxylin.
Preparation of peritoneal exudate macrophages and assays for
cytokine production in vitro. Thioglycolate-elicited murine peritoneal
exudate cells were collected as described.(15) Briefly, nude or
immunocompetent mice were injected intraperitoneally with
2 mL each of 3% fluid thioglycolate medium (Wako Pure
Chemical) and sacrificed 4 days later, followed by peritoneal
lavage with 10 mL of cold PBS. About 90% of the collected
peritoneal cells were positive for both Mac-1 (CD11b) and I-Ad
MHC class II as determined by staining with PE-conjugated
anti-Mac-1 Ab and fluorescein-isothiocyanate (FITC)–conjugated
I-Ad MHC class II (AMS-32.1; Pharmingen). Huh7 cells were
infected with rAds, at a MOI of 5 for 24 h. Aliquots of 105
macrophages were cocultured with 105 rAd-treated Huh7 cells
in 1.0 mL of culture media in 24-well tissue culture plates, and
treated with GCV for 2 days at 37°C. The concentrations of IL-10,
IL-12, IL-18, and IFN-γ in the media were quantified using
immunoassay kits (IL-10, IL-12, IFN-γ: Biosource International,
Camarillo, CA, USA; IL-18: Medical & Biological Laboratories,
Nagoya, Japan).
Rechallenge testing in nude mice. Nude mice were injected
subcutaneously with 5 × 106 HuH7 cells on day 0. On days 3
and 4, the subcutaneous tumors were injected with 5 × 107
TCID50 (100 μL) of Ad-tk, Ad-lacZ, or Ad-tk (fixed dose) plus
Ad-MCP1 (changed dose), and the mice were treated with
75 mg/kg GCV, injected into the peritoneal cavity, every day for
the next 5 days (days 5–9). Following complete eradication of
the primary tumors, the mice were subcutaneously rechallenged
on day 14 with 3 × 106 HuH7 cells at two sites, which were
more than 3 cm apart from the primary challenge site. Two of 10
(20%) mice treated with Ad-tk and four of 30 (13.3%) treated
with Ad-tk plus Ad-MCP1 did not show complete eradication of
the primary tumor by the final measurement and were therefore
excluded from the rechallenge experiment. Tumor sizes were
measured every 4 days after the second tumor injection, and
tumor volumes were calculated using the formula:
Animal studies in immunocompetent mice (ex vivo, in vivo, and
rechallenge). Six-week-old immunocompetent male BALB/c-jcl
mice (CLEA Japan) were injected subcutaneously with 1 × 105
BNL cells infected with each rAd at an in vitro MOI of 5 at the
both sides of the flank on day 0, and GCV was administered
intraperitoneally for the next 5 days (days 1–5). Tumor size was
measured every 7 days, and tumor volume was calculated using
the formula:
As with the experiments on nude mice, BALB/c-jcl mice were
injected subcutaneously with 1 × 105 BNL cells at the both sides
of the flank on day 0. On days 3 and 4, 5 × 105 TCID50 (100 μL)
of rAds were injected into the tumor. Then, GCV was administered
for the next 5 days (day 5–9), and tumor size was measured
every 3 days.
In another experiment, immunocompetent mice were injected
subcutaneously with 1 × 105 BNL cells infected with each rAd
at an in vitro MOI of 100 on day 0, and GCV was administered
intraperitoneally for the next 5 days (days 1–5). The primary
tumors were completely eradicated in all groups. These mice
were injected subcutaneously with 1 × 104 BNL cells on day 14
at two sites which were separate from the primary challenge
sites, and the tumor sizes were measured every 7 days after the
second tumor injection.
ELISA for serum IL-10, IL-12, and IL-18. Mouse sera were collected
prior to injection of subcutaneous primary tumors and on day 35
after tumor injection. IL-10, IL-12, and IL-18 concentrations
were measured using immunoassay kits (IL-12, Biosource
International; IL-18, Medical & Biological Laboratories).
Flow cytometry. Single-cell suspensions of splenocytes were
resuspended in PBS containing 1% bovine serum albumin and
0.1% sodium azide, and incubated for 30 min on ice with
FITC-conjugated rat antimouse-F4/80 (Serotec, Oxford, UK)
and PE-conjugated rat antimouse pan natural killer (NK) cells
(DX5; Pharmingen), with FITC-conjugated rat antimouse-CD3
(Pharmingen) and PE-conjugated rat antimouse CD11c (Pharmingen)
or with FITC-conjugated rat antimouse-CD8 (Pharmingen) and
PE-conjugated rat antimouse CD4 (Pharmingen). The cells were
washed, resuspended in PBS, and analyzed using a FACScan
with CellQuest software.
Statistical analysis. All results are expressed as means ± SE. The
statistical significance of differences between groups was evaluated
by the Mann–Whitney U-test.
Results
MCP-1 production by double infection with recombinant adenoviruses
in vitro. MCP-1 expression level by Ad-MCP1 alone was high
compared with double infection of Ad-lacZ plus Ad-MCP1
(Fig. 1a). The amounts of MCP-1 produced by Ad-tk plus Ad-MCP1
decreased rapidly after GCV administration due to Huh7 cell
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apoptosis induced by the HSV-tk/GCV system (Fig. 1a). Moreover,
the amounts of MCP-1 produced by Ad-tk plus Ad-MCP1 without
GCV administration were lower than those of Ad-lacZ plus
Ad-MCP1, presumably due to the MCP-1 promoter interference
by HSV-tk.
Next, production of MCP-1 in Huh7 cells double-infected
with Ad-tk (fixed dose) plus Ad-MCP1 (changed dose) was
measured. The amounts of MCP-1 were correlated with the
infectious dose of Ad-MCP1 in the presence of a fixed amount
of HSV-tk (Fig. 1b).
Antitumor effects of the HSV-tk/GCV system by codelivery of the
MCP-1 gene in an athymic nude mouse model of HCC. The in vivo
antitumor effects of double infection with rAds were analyzed
using athymic nude mice (Fig. 2a). The growth of subcutaneous
tumors was markedly suppressed in animals treated with Ad-tk
plus Ad-MCP1 (1:1) (tumor volume 32 days after injection, 44.4
± 22.5 mm3) or Ad-tk plus Ad-MCP1 (1:0.1) (37.4 ± 18.6 mm3),
as compared to those treated with Ad-tk alone (170.2 ± 49.8 mm3,
P < 0.05) (Fig. 2b). These observations indicated that optimal
amounts of MCP-1 are needed to eradicate tumor cells in the
presence of HSV-tk.
Recruitment and activation of macrophages into tumor tissues.
Macrophages play important roles in both Th1- and Th2-mediated
immune responses. Classical macrophage (M1 macrophages) are
also a major source of IL-12 and IL-18, whereas alternative
macrophages (M2 macrophages) are a source of IL-10.(9) IL-12
Fig. 1. Monocyte chemoattractant protein-1 (MCP-1) production of
recombinant adenoviruses in the presence of herpes simplex virus
thymidine kinase (HSV-tk). Aliquots of 1 × 105 Huh7 cells were seeded
in 1.0 mL of culture media in 24-well tissue culture plates. (a) Twenty-
four h later, the cells were treated with Ad-tk plus Ad-MCP1, Ad-lacZ
plus Ad-MCP1, or Ad-MCP1 at a multiplicity of infection (MOI) of 10,
and treated 72 h later with ganciclovir (GCV) (10 μg/mL). Every 24 h,
the medium was collected and replaced with the same volume of fresh
medium. (b) Twenty-four h later, the cells were doubly infected with
Ad-tk (fixed dose, at an MOI of 10) plus Ad-MCP1 (changed dose), and
the medium was collected 48 h later. The concentrations of MCP-1 were
evaluated using an immunoassay. Values are shown as the means ± SE
of duplicate experiments.
Fig. 2. The antitumor effects of the herpes simplex virus thymidine
kinase (HSV-tk)/ganciclovir (GCV) system by codelivery of monocyte
chemoattractant protein-1 (MCP-1) in a nude mouse model of
hepatocellular carcinoma (HCC). (a) Mice were injected subcutaneously
with 1 × 107 Huh7 cells at the both sides of the flank on day 0. On days
3 and 4, 1 × 107 TCID50 of Ad-tk, Ad-tk (1 × 10
7 TCID50, fixed dose) plus
Ad-MCP1 (1, 0.1, 0.01, or 0.001 × 107 TCID50, changed dose), or Ad-lacZ
was injected into the tumor, and the mice were injected
intraperitoneally (i.p.) with 75 mg/kg of GCV every day for the next
5 days (day 5–9). (b) Tumor size was measured every 3 days. The results
are shown as the means of two independent experiments.
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enhances the activities of NK cells and cytotoxic T lymphocytes
(CTL), and plays a key role in the induction of Th1-type
immune responses.(16) In addition, IL-18 is a proinflammatory
cytokine produced by activated macrophages, which has been
shown to induce Th1 cell development and NK cell activation in
combination with IL-12.(17) In contrast, the effects of IL-10 on
immune responses are mostly inhibitory.(18) Therefore, to evaluate
whether M1 macrophages recruited into tumor tissues following
infection with rAds were activated, IL-10, IL-12, IL-18, IFN-γ,
and VEGF expression were determined using real-time RT-PCR.
IL-12 and IL-18 mRNA levels were significantly increased
(P < 0.01), and that of IFN-γ mRNA tended to increase in
tumors treated with Ad-tk plus Ad-MCP1 (1:0.1) (Fig. 3a). In
contrast, IL-10 mRNA was significantly increased in tumors
treated with Ad-tk plus Ad-MCP1 (1:0.01) (P < 0.05) (Fig. 3a).
In addition, the VEGF mRNA level was significantly increased in
tumors treated with Ad-MCP1 (P < 0.01), and was significantly
decreased in tumors treated with Ad-tk plus Ad-MCP1 (1:0.1)
Fig. 3. Cytokine expression and macrophage recruitment in primary tumor tissues. In the experiment described in the legend to Fig. 2, tumor
tissues were resected 10 days after tumor injection. (a) Total RNA was extracted to determine cytokine mRNA levels by a real-time reverse
transcription–polymerase chain reaction as described in ‘Materials and Methods’. Cytokine mRNA expression was normalized to 18S rRNA and then
expressed as the fold change in mRNA expression as compared with control samples treated with phosphate-buffered saline. Splenocytes treated
with 0.1 μg/mL LPS were used as a positive control (data not shown). The results are shown as the means of two independent experiments. (b)
Tumor tissues were processed for immunohistochemical analysis using anti-Mac1 antibody as described in ‘Materials and Methods’. Representative
results from individual animals in each group are shown here.
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(P < 0.05) (Fig. 3a). Taken together, these observations indicated
that M1 macrophages were highly activated when tumors were
treated with the optimal dose of MCP-1 and HSV-tk.
Next, we evaluated whether there were differences in the
number of macrophages recruited into tumor tissues. The number
of accumulated Mac-1-positive cells in the tumors treated with
Ad-tk plus Ad-MCP1 (1:0.1) was comparable to that in those
treated with Ad-tk plus Ad-MCP1 (1:1) (Fig. 3b). These obser-
vations suggested that the number of recruited macrophages is
of little importance to the antitumor effects.
IL-10, IL-12, IL-18, and IFN-g production by coculture of apoptotic
Huh7 cells expressing MCP-1 and peritoneal macrophages in vitro.
It was reported that adenoviral-mediated overexpression of
MCP-1 differentially modulated the development of Th1 and
Th2–type responses.(19) To evaluate the differences in the
immunomodulatory effects of macrophages among double
infection of rAds, we measured IL-10, IL-12, IL-18, and IFN-γ
production by peritoneal exudate cells consisting mostly of
macrophages, when they were cocultured with Huh7 cells infected
with rAds. We found that peritoneal macrophages cocultured
with Huh7 cells treated with Ad-tk plus Ad-MCP1 (1:0.1) tended
to produce increased levels of IL-12, IL-18, and IFN-γ (Fig. 4).
On the other hand, the increase in amount of IL-10 in the double
infection groups was inversely proportional to the dosage of
MCP-1 vector (Fig. 4). These observations also suggest that the
optimal dose of MCP-1 and HSV-tk may induce M1 macrophage
activation.
Antitumor immunity in the rechallenge test of the HSV-tk/GCV
system by codelivery of the MCP-1 gene. After primary subcutaneous
Huh7 cells were completely eradicated with rAds, nude mice were
rechallenged with Huh7 cells to evaluate antitumor immunity
induced by MCP-1 plus HSV-tk. We found that the tumor regrowth
was significantly suppressed when the primary tumor cells had been
eradicated with Ad-tk plus Ad-MCP1 (1:0.1) as compared with
Ad-tk (tumor volume 40 days after rechallenge: 123.2 ± 77.2 mm3
vs 544.5 ± 161.6 mm3, respectively, P < 0.05) (Fig. 5). In addition,
tumor regrowth tended to be low when eradicated with Ad-tk
plus Ad-MCP1 (1:0.1) as compared with Ad-tk plus Ad-MCP1 (1:1)
(287.9 ± 137.1 mm3, P = 0.18) or Ad-tk plus Ad-MCP1 (1:0.01)
(269.7 ± 91.1 mm3, P = 0.24). Next, to evaluate immunomodulatory
effects of splenocytes, we examined IFN-γ expression using
real-time RT-PCR. IFN-γ mRNA levels were significantly increased
in the spleens of nude mice treated with Ad-tk plus Ad-MCP1
(1:0.1) (Fig. 5b). Consistent with our previous findings,(20) we
observed increased numbers of NK cells in the spleen and
rechallenged tumor tissues when treated with the 1:0.1 ratio of
Ad-tk and Ad-MCP1 (data not shown). These results indicated
that the optimal dose of MCP-1 induced beneficial antitumor
immunity in the presence of HSV-tk.
Antitumor effects and immunity of the HSV-tk/GCV system plus
MCP-1 treatment in an immunocompetent mouse model of HCC.
There is no CTL in athymic nude mice. Therefore, to evaluate
the Th1 cytokine response in the syngeneic system, the ex vivo
antitumor effects of double infection with rAds were analyzed
using immunocompetent BALB/c-jcl mice. The growth of
subcutaneous tumors treated with Ad-tk plus Ad-MCP1 (1:1,
1:0.1) was comparable to that in nude mice (P < 0.01), excluding
the group in which the dose of MCP-1 was small (1:0.01)
(Fig. 6a).
In the next experiment, after the BALB/c mice developed
tumor mass following the injection with non-infected BNL cells,
we infected the resultant tumors with Ad-tk plus Ad-MCP1 and
treated the animals with GCV using the same procedures as the
experiments with nude mice. Tumor growth was apparently
retarded when treated with Ad-tk plus Ad-MCP1 (1:1) (P < 0.05)
and (1:0.1) (P < 0.01) as compared with Ad-tk alone (Fig. 6b).
However, the treatments failed to eradicate tumors completely,
probably because the infection efficiency was not sufficient
under these conditions.
Thus, we chose the ex vivo infection experiment in the immu-
nocompetent mouse model, to evaluate whether rechallenged
tumors could be rejected in the mice in which the primary
tumors had been completely eradicated. The immunocompetent
mice were rechallenged with BNL 1ME A.7R.1 (BNL) cells
Fig. 4. Cytokine production by peritoneal
macrophages cocultured with Huh7 cells infected
with rAds in vitro. Huh7 cells were infected with
each rAd at a multiplicity of infection (MOI) of 5
and treated with ganciclovir (GCV) for 24 h.
Aliquots of 105 peritoneal exudate macrophages
were cocultured with 105 rAd-treated Huh7 cells
for 2 days, and the concentrations of IL-10, IL-12,
IL-18, and IFN-γ in the media were evaluated by
immunoassay. Values are shown as the means ±
SE of duplicate experiments.
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using the same procedures as in the experiments with nude mice.
Although the inhibition of tumor regrowth was significantly
lower when they had been eradicated with Ad-tk plus Ad-MCP1
(1:0.1) as compared with Ad-tk (tumor volume 42 days after
rechallenge: 263.9 ± 87.8 mm3 vs 669.5 ± 158.3 mm3, respec-
tively, P < 0.05), it also tended to be lower when the primary
tumor cells had been eradicated with Ad-tk plus Ad-MCP1 (1:1)
(tumor volume 42 days after rechallenge: 372.5 ± 157.8 mm3)
(Fig. 6c), similar to the observations in athymic nude mice.
Next, we examined IL-10, IL-12, and IL-18 production on
day 35 after tumor injection. Serum concentrations of IL-12 and
IL-18 tended to be higher in mice treated with Ad-tk plus
Ad-MCP1 (1:0.1) as compared with those treated with Ad-tk,
Ad-tk plus Ad-MCP1 (1:1), or Ad-tk plus Ad-MCP1 (1:0.01)
(Fig. 6d). In contrast, the increase in amount of serum IL-10 in
the double infection groups was inversely proportional to the
dosage of MCP-1 (Fig. 6d). These observations were consistent
with the data shown in Figs 3 and 4.
Finally, to monitor the activation state of innate and acquired
immunity in extrahepatic lymphoid organs, we examined the
numbers of immune cells in the spleen on day 35 after tumor
injection by FACS analysis. The numbers of F4/80-positive cells
tended to be higher in the Ad-tk plus Ad-MCP1 (1:1) and Ad-tk
plus Ad-MCP1 (1:0.1) groups, and the numbers of DX5-positive
cells tended to be higher in the Ad-tk plus Ad-MCP1 (1:0.1)
group (Fig. 6e). Furthermore, the numbers of CD3-, CD4-, and
CD8-positive cells were increased in the immunocompetent
mice in the order of Ad-tk plus Ad-MCP1 (1:0.1), Ad-tk plus
Ad-MCP1 (1:1), and Ad-tk plus Ad-MCP1 (1:0.01) (Fig. 6e).
Taken together, these results confirmed that treatment with Ad-tk
plus Ad-MCP1 (1:0.1) resulted in the development of beneficial
antitumor immunity in both immunodeficient and immunocom-
petent animals.
Discussion
HCC is one of the most common cancer-related causes of death,
and is resistant to anticancer drugs.(21) Although gene therapy
has the potential to more effectively induce tumor cell death as
compared to conventional treatment, there have been no previous
comparisons with regard to the optimal doses of vectors in
combined gene therapy. Whereas the amounts of MCP-1 were
correlated with the infectious dose of Ad-MCP1 in the presence of
a fixed dose of Ad-tk, MCP-1 expression level in the presence of
intracellular HSV-tk was inhibited as compared with coinfection
with Ad-MCP1 plus Ad-lacZ, suggesting that HSV-tk may influence
the efficiency of transcription in the transformed cells. In
addition, MCP-1 expression level by Ad-MCP1 alone was high
as compared with double infection with Ad-MCP1 plus Ad-
lacZ, which was probably due to promoter interference. On the
other hand, our previous study demonstrated that the levels of
HSV-tk expression in cells cotransfected with Ad-tk plus Ad-
MCP-1 were comparable to those of Ad-tk alone or Ad-tk plus
Ad-lacZ.(3) The effect of a bicistronic rAd expressing mainly
HSV-tk was clearly stronger than that of a bicistronic rAd
expressing mainly MCP-1. Therefore, we proposed that theFig. 5. Nude mice were injected subcutaneously with 5 × 106 Huh7
cells on day 0. On days 3 and 4, 5 × 107 TCID50 of Ad-tk (100 μL), Ad-tk
(1 × 107 TCID50, fixed dose) plus Ad-MCP1 (1, 0.1, 0.01, or 0.001 × 10
7
TCID50, changed dose), or Ad-lacZ was injected into the tumor, and the
mice were injected intraperitoneally with 75 mg/kg of ganciclovir (GCV)
every day for the next 5 days (day 5–9). Following complete eradication
of the primary tumors, the mice were subcutaneously rechallenged on
day 14 with 3 × 106 Huh7 cells at the other sites. (a) Tumor size was
measured every 4 days. (b) In another series of experiments, the spleen
was resected on day 16 after tumor injection, and IFN-γ, mRNA levels
were evaluated using real-time reverse transcription–polymerase chain
reaction. The results are shown as the means of two independent
experiments. PBS, phosphate-buffered saline.
Fig. 6. Antitumor effects of the herpes simplex virus thymidine kinase
(HSV-tk)/ganciclovir (GCV) system by codelivery of monocyte
chemoattractant protein-1 (MCP-1) in an immunocompetent mouse
model of HCC. (a) Mice were injected subcutaneously with 1 × 105 BNL
cells infected with each rAd at an in vitro multiplicity of infection (MOI)
of 5 at the both sides of the flank on day 0. GCV was administered
intraperitoneally for the next 5 days (days 1–5), and tumor size was
measured every 7 days. (b) BALB/c-jcl mice were injected subcutaneously
with 1 × 105 BNL cells at the both sides of the flank on day 0. On days
3 and 4, 5 × 105 TCID50 (100 μL) of rAds were injected into the tumor.
Then, GCV was administered for the next 5 days (day 5–9), and tumor
size was measured every 3 days. (c) BALB/c-jcl mice were injected
subcutaneously with 1 × 105 BNL cells infected with each rAd at an in
vitro MOI of 100 on day 0, and GCV was administered intraperitoneally
for the next 5 days (days 1–5). The primary tumors were completely
eradicated in all groups. These mice were injected subcutaneously with
1 × 104 BNL cells at other sites on day 14, and the tumor sizes were
measured every 7 days after the second tumor injection. (d) Mouse sera
were collected prior to subcutaneous injection of primary tumor cells
(untreated), after treatment of the tumor with each rAd, and 2 days
after rechallenge with HuH7 cells, and IL-12 and IL-18 concentrations
were measured using immunoassay kits. (e) The spleen was removed to
obtain single cell suspensions on day 35 after tumor injection. Surface
expression of DX5, F4/80, CD3, CD4, CD8, and CD11c in cell populations
obtained from the spleen were assessed by FACS. The results are
representative of two independent experiments.
Tsuchiyama et al. Cancer Sci | October 2008 | vol. 99 | no. 10 | 2081
© 2008 Japanese Cancer Association
2082 doi: 10.1111/j.1349-7006.2008.00951.x
© 2008 Japanese Cancer Association
HSV-tk/GCV system should mainly be used and the use of
MCP-1 was supported in our experimental models, although
their efficiencies may vary depending on the nature of the cell
type and reporter genes used.(22)
Th1 cytokine expression levels in tumors treated with Ad-tk
plus Ad-MCP1 (1:0.1) were higher than those treated with Ad-
tk plus Ad-MCP1 (1:1) or (1:0.01). Moreover, macrophages pro-
duced large amounts of Th1 cytokines when cocultured with
apoptotic HCC cells induced by Ad-tk plus Ad-MCP1 (1:0.1).
In contrast, whereas the amounts of Th2 cytokines were rela-
tively high in Ad-tk plus Ad-MCP1 (1:0.01), they were low in
Ad-tk plus Ad-MCP1 (1:1). There were almost no differences in
the number of macrophages among the tumors treated with various
combinations of HSV-tk and MCP-1. Therefore, the types of
activated macrophages may be important rather than the numbers
recruited and activated. The ratio of IL-12 to IL-10 can be used
as a simple metric to classify activated macrophages into two
categories, M1 or M2.(23,24) M1 macrophages are potent effector
cells that kill microorganisms and tumor cells and produce large
amounts of proinflammatory cytokines, particularly IL-12. In
contrast, M2 macrophages, a producer of IL-10, tune inflamma-
tory responses and adaptive Th1 immunity, scavenge debris, and
promote angiogenesis, tissue remodeling, and repair. The M1/M2
dichotomy of macrophage polarization can elicit both anti- and
pro-tumoral activities.(25)
MCP-1 is known to facilitate tumor growth under different
conditions, probably by promoting angiogenesis.(8) In the present
study, the VEGF expression levels in tumors treated with Ad-tk
plus Ad-MCP1 (1:0.1) were low as compared with those treated
with Ad-MCP1 alone or Ad-tk plus Ad-MCP1 (1:1 and 1:0.01).
A previous study indicated that monocyte recruitment is depend-
ent on the level of MCP-1 secreted by the tumor cells and that
the effects of monocyte infiltration on tumor growth are dependent
on their levels of infiltration.(26) MCP-1 secreted by apoptotic
Huh7 cells may have recruited macrophages more efficiently to
these apoptotic cells, thereby resulting in a greater deleterious
effect on tumor formation. Therefore, we propose that it is necessary
to set the appropriate dosages of the two vectors in the HSV-tk
plus MCP-1 system.
Recently, we found that the HSV-tk/GCV system, together
with delivery of MCP-1, eradicated HCC and exerted prolonged
antitumor effects by activating macrophages and NK cells.(20) In
this study, the antitumor immunity increased in mice treated
with Ad-tk plus Ad-MCP1 (1:0.1). Several investigators have
reported that dying HSV-tk-modified cells released soluble factors,
including cytokines.(27,28) These factors could in turn affect the
tumor microenvironment, leading to necrosis and inflammation,
infiltration of immune cells, up-regulation of costimulatory
molecules, and generation of an antitumorigenic immune
responses.(28,29) In this immunotherapeutically favorable setting,
the optimal dose of MCP-1 with HSV-tk inside the same cell may
stimulate tumor-specific immune-mediated cell killing. Conse-
quently, the delivery of an optimal amount of rAd expressing
MCP-1 enhanced the antitumor effects of the HSV-tk/GCV system
in a model of HCC, and the effects were related to the balance
of Th1 and Th2–type cytokines.
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